BVS Bioventus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BVS

Price (delayed)

$3.97

Market cap

$314.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$672.17M

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations ...

Highlights
The quick ratio has surged by 65% year-on-year and by 4.6% since the previous quarter
Bioventus's EPS has increased by 15% from the previous quarter and by 3.9% YoY
Bioventus's equity has decreased by 47% YoY and by 2.2% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.bioventus.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of BVS
Market
Shares outstanding
79.17M
Market cap
$314.29M
Enterprise value
$672.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
0.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31
Earnings
Revenue
$512.35M
EBIT
-$115.47M
EBITDA
-$58.1M
Free cash flow
$7.98M
Per share
EPS
-$2.49
Free cash flow per share
$0.13
Book value per share
$2.2
Revenue per share
$8.18
TBVPS
$5.13
Balance sheet
Total assets
$810.91M
Total liabilities
$589.79M
Debt
$394.85M
Equity
$173.59M
Working capital
$92.5M
Liquidity
Debt to equity
2.27
Current ratio
1.53
Quick ratio
0.91
Net debt/EBITDA
-6.16
Margins
EBITDA margin
-11.3%
Gross margin
64.1%
Net margin
-30.5%
Operating margin
-23.5%
Efficiency
Return on assets
-18.7%
Return on equity
-86.5%
Return on invested capital
-22.1%
Return on capital employed
-18.2%
Return on sales
-22.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BVS stock price

How has the Bioventus stock price performed over time
Intraday
0.25%
1 week
-0.25%
1 month
-20.92%
1 year
324.46%
YTD
-24.67%
QTD
-23.65%

Financial performance

How have Bioventus's revenue and profit performed over time
Revenue
$512.35M
Gross profit
$328.19M
Operating income
-$120.39M
Net income
-$156.23M
Gross margin
64.1%
Net margin
-30.5%
Bioventus's operating margin has increased by 36% YoY and by 13% QoQ
The operating income has grown by 36% YoY and by 12% from the previous quarter
BVS's net margin is up by 16% QoQ
The company's net income rose by 14% QoQ

Growth

What is Bioventus's growth rate over time

Valuation

What is Bioventus stock price valuation
P/E
N/A
P/B
1.8
P/S
0.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31
Bioventus's EPS has increased by 15% from the previous quarter and by 3.9% YoY
Bioventus's equity has decreased by 47% YoY and by 2.2% from the previous quarter
BVS's price to book (P/B) is 29% more than its last 4 quarters average of 1.4
BVS's P/S is 23% above its last 4 quarters average of 0.4

Efficiency

How efficient is Bioventus business performance
The ROE has dropped by 114% year-on-year and by 3.8% since the previous quarter
The return on assets has dropped by 52% year-on-year
Bioventus's ROS has increased by 40% YoY and by 27% from the previous quarter
The return on invested capital has increased by 33% year-on-year and by 14% since the previous quarter

Dividends

What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BVS.

Financial health

How did Bioventus financials performed over time
Bioventus's total assets is 37% more than its total liabilities
BVS's current ratio has surged by 70% year-on-year
The quick ratio has surged by 65% year-on-year and by 4.6% since the previous quarter
BVS's debt is 127% higher than its equity
BVS's debt to equity has surged by 76% year-on-year and by 2.3% since the previous quarter
Bioventus's equity has decreased by 47% YoY and by 2.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.